Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer, Women's Studies, Hematology |
| Therapuetic Areas: | Hematology, Oncology, Reproductive |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2009 |
A Phase II Trial of Clofarabine and Cytarabine to Treat Minimal Residual Disease (MRD) in Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them
from dividing. Giving clofarabine together with cytarabine may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving clofarabine together with
cytarabine works in treating patients with acute myeloid leukemia with minimal residual
disease.
PRIMARY OBJECTIVES:
I. To test the ability of chlofarabine + ara-C to eliminate minimal residual disease (MRD)
in acute myeloid leukemia patients whose bone marrows exhibit complete remission by
morphology.
SECONDARY OBJECTIVES:
I. To determine the duration of complete remission after this treatment to minimize minimal
residual disease.
OUTLINE: Patients receive filgrastim (G-CSF) subcutaneously once daily on days 1-5 and
clofarabine IV over 1 hour and cytarabine IV on days 2-5. Beginning approximately 1 month
later, patients may receive one additional course of treatment in the absence of disease
progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 2 years, and
then annually for 3 years.
We found this trial at
1
site
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
